High-dose oral terbinafine in the treatment of pediatric tinea capitis under 2 years old

Dermatol Ther. 2022 Apr;35(4):e15320. doi: 10.1111/dth.15320. Epub 2022 Jan 20.

Abstract

Tinea capitis is the most common pediatric dermatophytosis of the scalp and hair follicles that require oral antifungals therapy. It usually occurs in children between 3 and 7 years old, whereas it is rarely reported in children under 2 years old. Although oral terbinafine has been broadly used to treat tinea capitis, it is not approved for pediatric patients under 2 years old. Previous studies reported that a doubled oral terbinafine dose could improve the cure rates of tinea capitis due to Microsporum canis. However, the doses are all not strictly weight-based. Here, we report four pediatric tinea capitis patients under 2 years of age who were treated with a high, strictly weight-based dose of oral terbinafine therapy (10 mg/kg/day). We determine the efficacy and safety of this novel oral terbinafine therapy schedule. It may be a promising therapy to treat pediatric tinea capitis under 2 years old.

Keywords: children under 2 years old; terbinafine; tinea capitis.

MeSH terms

  • Administration, Oral
  • Antifungal Agents*
  • Child
  • Child, Preschool
  • Humans
  • Infant
  • Naphthalenes
  • Terbinafine
  • Tinea Capitis* / diagnosis
  • Tinea Capitis* / drug therapy
  • Treatment Outcome

Substances

  • Antifungal Agents
  • Naphthalenes
  • Terbinafine